This bill proposes to amend the Social Security Act to exempt specific orally administered drugs from the Medicare Part D manufacturer discount program. The current program requires manufacturers to provide discounts on certain drugs, but this legislation seeks to create an exception for a particular category of medications. The exemption would apply to orally administered drugs that were initially approved as new drugs under the Federal Food, Drug, and Cosmetic Act. Additionally, these drugs must have been granted a narrow exception by the Centers for Medicare & Medicaid Services (CMS), allowing their reclassification as noninnovator multiple source drugs under the Medicaid drug rebate program. By excluding these drugs, the bill would remove the obligation for their manufacturers to participate in the Part D discount program, potentially impacting drug pricing and access for beneficiaries.